. 2009 Sep 26;101(1):22–28. doi: 10.1111/j.1349-7006.2009.01373.x

Table 2.

Randomized trials of first‐line chemotherapy in patients with good‐risk metastatic disease

Source	No. patients	Risk system (%)	Regimens (%)	PFS	OS	Conclusion
Loehrer et al. ⁽ ²⁵ ⁾	171	Indiana⁽ ¹¹ ⁾	BEP × 3	86†	95	BEP superior
Loehrer et al. ⁽ ²⁵ ⁾	171	Indiana⁽ ¹¹ ⁾	EP × 3	69	86	BEP superior
de Wit et al. ⁽ ²⁶ ⁾	395	MRC/EORTC⁽ ¹² ⁾	BE360P × 4	93	97	BEP superior
de Wit et al. ⁽ ²⁶ ⁾	395	MRC/EORTC⁽ ¹² ⁾	E360P × 4	90	94	BEP superior
Toner et al. ⁽ ²⁷ ⁾	166	MSKCC⁽ ¹⁰ ⁾	BEP × 3	90	96	BEP superior
Toner et al. ⁽ ²⁷ ⁾	166	MSKCC⁽ ¹⁰ ⁾	mBEP × 4	81	84	BEP superior
de Wit et al. ⁽ ²⁸ ⁾	792	IGCCCG⁽ ¹⁴ ⁾	BEP × 3	90	97	Equivalent efficacy
de Wit et al. ⁽ ²⁸ ⁾	792	IGCCCG⁽ ¹⁴ ⁾	BEP × 3 + EP × 1	89	97	Equivalent efficacy
Culine et al. ⁽ ³⁰ ⁾	257	IGR⁽ ¹³ ⁾	BEP × 3	91‡	96	Equivalent efficacy
Culine et al. ⁽ ³⁰ ⁾	257	IGR⁽ ¹³ ⁾	EP × 4	86	92	Equivalent efficacy

†Failure‐free survival; ‡event‐free survival. E360, etoposide reduced to 360 mg/m³ per cycle; mBEP, modified BEP (bleomycin reduced to 30 U per cycle; etoposide reduced to 360 mg/m³ per cycle); OS, overall survival; PFS, progression‐free survival; MRC, Medical Research Council; EORTC, European Organization for Research and Treatment of Cancer; MSKCC, Memorial Sloan‐Kettering Cancer Center; IGCCCG, International Germ Cell Cancer Consensus Group; IGR, Institut Gustave Roussy.